Drug Trial Radar · NCT07901244
An Open-Label Study to Determine if BHV-1300 is Safe in Adults With Graves' Disease
Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
356
Planned (sponsor's estimate)
Start
Oct 2026
Primary completion
Dec 2028
Study completion Jan 2029
Sponsor
- Lead sponsor
- Biohaven Therapeutics Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To study the long-term safety and tolerability of BHV-1300
Conditions
- Graves' Disease
Interventions
BHV-1300Drug
delivered subcutaneously via autoinjector
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of SAEs, severe AEs, AEs leading to discontinuation, or deathsTime frame: Baseline to Week 52
- Frequency of clinically significant laboratory abnormalitiesTime frame: Baseline to Week 52
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.